On August 11, 2026, 908 Devices Inc. reported preliminary financial results for the second quarter and fiscal year ended December 31, 2026. Revenue increased 23% year-over-year to $16.1 million, with recurring revenue representing 31% of total revenues. The company raised its full-year 2026 revenue guidance range to $68.0 million–$70.0 million, reflecting 21% to 25% year-over-year growth. Adjusted EBITDA loss narrowed by more than half compared to the prior year period. The filing also notes the acquisition of NIRLAB SA for $13.5 million and a subsequent $6 million ProtectIR order from an Asia-Pacific corrections agency. 908 Devices Inc. designs and manufactures handheld chemical analysis tools for health, safety, and defense applications.

On July 8, 2026, 908 Devices Inc. issued 3,213,583 shares of common stock to satisfy earnout obligations related to an Equity Purchase Agreement dated April 29, 2024, for the acquisition of RedWave Technology. The issuance followed the achievement of a revenue threshold of $37 million from RedWave products and services between May 1, 2024, and April 30, 2026. This issuance fully satisfies the company's obligations regarding the Earnout Consideration. The company develops and manufactures analytical instrumentation for the life sciences and environmental markets.